H. R. 1672, titled the "Maintaining Investments in New Innovation Act," is proposed to amend the Social Security Act. It aims to protect access to genetically targeted technologies by changing how certain drug products are classified. This includes redefining qualifying single-source drugs by...
Simple Explanation
H.R. 1672 is a rule that aims to help drug makers keep their special rights to sell new, genetically-targeted medicines for a longer time, which could help them make more money but might also mean these medicines stay pricey for a bit longer.